🩺 pharmaadvance.in
🔬 Dermatology Scoring System
Clinical severity & causality instruments · interactive calculators
⚕
Clinical decision-support / educational use only. These calculators assist documentation — they do not replace clinical judgement, examination, or current guidelines. Verify every formula and cut-off against the primary source before acting on a result. Several instruments are copyrighted by their authors and may require a licence for clinical, commercial or digital use — see References & Source Credits below.
Quality of Life
5 tools
😊
DLQI
Dermatology Life Quality Index
Rate each — 0 Not at all · 1 A little · 2 A lot · 3 Very much
DLQI Score
—
Range 0–30 · Score >10 = biologic eligibility threshold
🧒
cDLQI
Children's Dermatology Life Quality Index (4–16 yrs)
Parent/child-reported · 0=Not at all / Not relevant · 1=A little · 2=A lot · 3=Very much
cDLQI Score
—
0–1 No effect · 2–6 Small · 7–12 Moderate · 13–18 Very large · 19–30 Extremely large effect on child's QoL
📋
CADI
Cardiff Acne Disability Index
Each item 0–3 · Reporting last month
CADI Score
—
0–3 Minimal · 4–7 Moderate disability · 8–15 Severe disability
💜
PsoriQoL
Psoriasis-specific QoL index (25 items)
PsoriQoL is a 25-item patient-reported measure. Each item is answered True (1) or False (0). Higher score = worse QoL.
Items cover: physical function, emotional wellbeing, embarrassment, treatment burden, social activities. Validated specifically for plaque psoriasis. Administer the full patient-reported questionnaire; enter the count of "True" answers below.
Items cover: physical function, emotional wellbeing, embarrassment, treatment burden, social activities. Validated specifically for plaque psoriasis. Administer the full patient-reported questionnaire; enter the count of "True" answers below.
0
PsoriQoL Score
—
Higher score = worse QoL · severity bands shown are indicative, not formally validated cut-offs
🧠
Skindex-16
Emotional & Functional Impact
Skindex-16 — 3 domains, each item rated 0–6 (Never → Always):
• Symptoms (4 items): itch, burn, pain, irritation
• Emotions (7 items): worry, embarrassment, frustration
• Functioning (5 items): daily tasks, social interactions
Domain score = mean × 100/6. Higher score = worse QoL.
Administer the validated paper/digital patient-report form.
• Symptoms (4 items): itch, burn, pain, irritation
• Emotions (7 items): worry, embarrassment, frustration
• Functioning (5 items): daily tasks, social interactions
Domain score = mean × 100/6. Higher score = worse QoL.
Administer the validated paper/digital patient-report form.
Psoriasis
6 tools
⭐
PASI ⭐ Gold Standard
Psoriasis Area & Severity Index
Intensity 0–4 · Area: 0=0% 1=<10% 2=10-29% 3=30-49% 4=50-69% 5=70-89% 6=90-100%
PASI Score
—
PASI 75 (≥75% reduction from baseline) = standard success benchmark
📐
BSA
Body Surface Area — % Skin Involved
Enter % involvement per region (1 palm ≈ 1%)
0
0
0
0
0
0
Total BSA Involved
—
📊
PGA
Physician's Global Assessment
Select overall disease severity
PGA Score
—
Treatment target: PGA 0 or 1 (Clear / Almost Clear)
📈
PLSI ⚠ Verify source
Psoriasis Log-based Severity Index
⚠ Unverified instrument. No validated published tool was located under the name "PLSI" or this exact formula. Treat as a non-standard / experimental calculation only, or remove. For validated psoriasis extent/severity use PASI or BSA above.
Formula as implemented: PLSI = 3.5 × log₁₀(1 + BSA) × Severity grade (0–4)
0
PLSI Score
—
Indicative bands only · 0–5 Mild · 6–14 Moderate · 15–28 Severe
💅
NAPSI
Nail Psoriasis Severity Index
Scoring per nail:
Matrix signs (pitting, leukonychia, red spots in lunula, crumbling): 0=none, 1–4=quadrants involved
Nail Bed signs (onycholysis, oil drop, subungual hyperkeratosis, splinter haemorrhage): same 0–4 scale
Matrix signs (pitting, leukonychia, red spots in lunula, crumbling): 0=none, 1–4=quadrants involved
Nail Bed signs (onycholysis, oil drop, subungual hyperkeratosis, splinter haemorrhage): same 0–4 scale
NAPSI Score
—
Each nail max 8 pts × 10 fingernails = 80 max · include 10 toenails for 0–160 · mNAPSI uses target nail only
🦴
DAPSA
Disease Activity in Psoriatic Arthritis
0
0
0
0
0
DAPSA Score
—
Remission ≤4 · Low ≤14 · Moderate ≤28 · High >28
Acne
6 tools
🔬
GAGS
Global Acne Grading System
Grade: 0=None · 1=Comedones · 2=Papules · 3=Pustules · 4=Nodules
GAGS Score
—
📋
IGA
Investigator's Global Assessment
IGA Score
—
Clinical trial endpoint: IGA ≤1
🔴
Pillsbury Scale
Acne Grade I–IV (Classic)
Pillsbury Grade
—
Grade III–IV: consider systemic therapy
🏷️
Leeds Revised Acne Grading
0.5–12 Visual Reference Scale
Leeds Grade
—
Grade ≥5 = moderate–severe; consider oral therapy
🔖
Goodman & Baron's Scar Score
Acne Scar Severity — Qualitative & Quantitative
Qualitative Grading System (select dominant scar type)
Quantitative Score (optional) — Count × Weight
Quantitative weights: Macular (×1) · Mild atrophic rolling (×2) · Moderate atrophic (×3) · Punched-out/boxcar (×4) · Deep punched-out/ice-pick (×5) · Hypertrophic keloid (×7)
0
0
0
0
0
0
Acne Scar Score
—
Quantitative score guides treatment intensity: mild <15 · moderate 15–30 · severe >30
Androgenetic Alopecia (AGA)
2 tools
♂
Hamilton-Norwood Scale
Male Pattern Baldness (Types I–VII)
Select the Hamilton-Norwood type that best matches the patient
Hamilton-Norwood Type
—
Type III–IV: topical minoxidil + finasteride · Type V–VII: consider hair transplant
♀
Ludwig / Savin Scale
Female Pattern Hair Loss (Grade I–III)
Select Ludwig grade for crown/vertex thinning in female patients
Ludwig Grade
—
All grades: minoxidil 2–5% · investigate hormonal causes · Grade III: specialist referral
Atopic Dermatitis
4 tools
🌡️
SCORAD
SCORing Atopic Dermatitis
A — Extent (% BSA involved)
0
B — Intensity signs (0=None · 1=Mild · 2=Moderate · 3=Severe)
C — Subjective symptoms (VAS 0–10 each)
0
0
SCORAD Score
—
📊
EASI
Eczema Area & Severity Index
Signs 0–3 · Area 0–6
EASI Score
—
EASI-50/75/90 = treatment benchmarks
🩺
AD-PGA
AD Physician's Global Assessment
Select the overall AD severity grade
AD-PGA Score
—
Target: AD-PGA 0–1 · Biologics eligibility: moderate–severe (≥3)
📐
ADSI
Atopic Dermatitis Severity Index
Rate each sign 0–3: 0=None · 1=Mild · 2=Moderate · 3=Severe
ADSI Score
—
0–5 Mild · 6–10 Moderate · 11–15 Severe
Vitiligo
3 tools
🌀
VASI
Vitiligo Area Scoring Index
1 Hand Unit (HU) = palm + 5 digits ≈ 1% BSA ·
Formula: Region VASI = Hand Units × Depigmentation% ·
Total VASI = Σ All Region Scores
📷 Depigmentation Visual Reference Guide
0%
No depigmentation
10%
Specks only
25%
Pigmented > depigmented
50%
Equal pigment/depigment
75%
Depigmented > pigmented
90%
Speckled pigment
COMPLETELY WHITE
100%
Completely white — no pigment
VASI Score
—
VASI-50/75/90 = treatment benchmarks · Max theoretical ~100
📏
Vitiligo BSA
% Body Surface Area depigmented
Estimate % depigmented area per region (1 palm ≈ 1% BSA)
0
0
0
0
0
0
Vitiligo BSA
—
<10% Localised · 10–50% Generalised · >50% Universal vitiligo
📅
VIDA
Vitiligo Disease Activity Score
VIDA Score
—
Urticaria
3 tools
🪲
UAS7
7-day Urticaria Activity Score
Wheals 0–3 · Itch 0–3 per day
UAS7 Score
—
Well-controlled ≤6 · Complete response = 0
✅
UCT
Urticaria Control Test
UCT Score
—
≥12 = well-controlled · <12 = poorly controlled
💧
AAS
Angioedema Activity Score
AAS records 5 items (each 0–3) on days a patient has angioedema → daily score 0–15. Validated forms sum daily scores over 7 or 28 days (AAS7 max 105, AAS28 max 420). Below: enter one representative day; the optional day count gives a rough aggregate.
1
AAS Daily Score
—
Melasma
2 tools
☀️
MASI
Melasma Area & Severity Index
MASI Score
—
≥50% reduction = significant response
🌤️
Modified MASI (mMASI)
Simplified — excludes Homogeneity
mMASI = Σ (weight × Area × Darkness) — homogeneity excluded
mMASI Score
—
mMASI 0–24 · Better inter-rater reliability than full MASI
Hair Loss (Alopecia Areata)
1 tool
💇
SALT
Severity of Alopecia Tool
0
0
0
0
SALT Score
—
S0=0% · S1=1-25% · S2=26-50% · S3=51-75% · S4=76-99% · S5=100%
Hirsutism
1 tool
🌿
Ferriman-Gallwey Score
Androgen-dependent hair growth in women
Score each site 0–4: 0=None · 1=Fine vellus · 2=Few terminal hairs · 3=More terminal hairs · 4=Frank hirsutism
Ferriman-Gallwey Score
—
≥8 = hirsutism (European women) · ≥6 = hirsutism (Asian women) · Investigate for PCOS/adrenal/ovarian causes
Pemphigus & Mucous Membrane Pemphigoid
2 tools
🫧
ABSIS
Autoimmune Bullous Skin Disorder Intensity Score
ABSIS — Validated for pemphigus vulgaris and bullous pemphigoid. Skin component (max 150) + Oral mucosa component (max 56).
Skin Component — % BSA affected
0
Oral Mucosa Component
0
ABSIS Score
—
Indicative: Mild <17 · Moderate 17–45 · Severe >45 · Complete remission = 0 · simplified implementation — verify against original ABSIS form
🔵
PDAI
Pemphigus Disease Area Index
Score activity (active lesions) and damage (post-inflammatory) for each region
PDAI Score
—
Minimal ≤8 · Moderate 9–24 · Severe ≥25 · simplified region weighting — verify against full PDAI form
Erythroderma
1 tool
🔥
EPICS ⚠ Verify source
Erythroderma Severity & Prognosis Index
⚠ Unverified instrument. No validated published tool named "EPICS" for erythroderma was located. Treat this as an internal severity checklist only — it is not a recognised, validated score. Erythroderma severity is usually assessed clinically alongside cause-specific tools.
Rate each parameter 0–4
EPICS Score
—
Indicative only · 0–6 Mild · 7–12 Moderate · 13–20 Severe
Hidradenitis Suppurativa (HS)
2 tools
🌑
Hurley Staging System
HS Disease Staging (Stages I–III)
Select the Hurley stage that best represents the patient's HS
Hurley Stage
—
Stage I: topical · Stage II: oral antibiotics + biologics · Stage III: biologics + surgical
🔴
IHS4
International Hidradenitis Suppurativa Severity Score
IHS4 — Formula: (Nodules × 1) + (Abscesses × 2) + (Draining tunnels/sinuses × 4)
0
0
0
IHS4 Score
—
Mild ≤3 · Moderate 4–10 · Severe ≥11
Systemic / Connective Tissue Disease
3 tools
🫱
MRSS
Modified Rodnan Skin Score (Systemic Sclerosis)
MRSS — 17 body areas palpated and graded 0–3:
0 = Normal · 1 = Mild thickening · 2 = Moderate, can't pinch · 3 = Severe, bound to underlying tissue
0 = Normal · 1 = Mild thickening · 2 = Moderate, can't pinch · 3 = Severe, bound to underlying tissue
MRSS Score
—
0–14 Mild · 15–29 Moderate · ≥30 Severe SSc skin involvement
🦋
SLEDAI-2K
SLE Disease Activity Index
SLEDAI-2K — Only score features present in the last 10 days. Each item has a weighted score (1–8).
SLEDAI-2K Score
—
0=No activity · 1–5=Mild · 6–10=Moderate · 11–19=High · ≥20=Very high activity
🔷
Vancouver Scar Scale
Keloid / Hypertrophic Scar Assessment
Assess each parameter of the scar
Vancouver Scar Scale
—
0 = Normal skin · 13 = Severe scar · Guides scar treatment selection
Severe Cutaneous Adverse Reactions (SCAR)
3 tools
🔥
SCORTEN
SJS/TEN Mortality Predictor
⚠️ SCORTEN — Validated ICU mortality predictor. Calculate within 24–48 h of admission. Each criterion = 1 point.
+1
+1
+1
+1
+1
+1
+1
SCORTEN Score
—
⚡
CRISTEN ⚠ Mislabelled
SJS/TEN — see note before use
⚠ Name vs purpose mismatch. The published CRISTEN (J Allergy Clin Immunol Pract, 2023) is a mortality predictor for SJS/TEN — like SCORTEN — not a drug-causality tool. The questions below are a causality checklist. For validated drug causality in SJS/TEN, use ALDEN (Sassolas et al., Clin Pharmacol Ther 2010). Recommend renaming this card "ALDEN-style causality" or replacing it.
Causality Score
—
Indicative only · ≥6 Probable/Definite · 3–5 Possible · <3 Unlikely
🚨
DRESS / RegiSCAR Score
Drug Reaction with Eosinophilia & Systemic Symptoms
DRESS RegiSCAR Score
—
<2=No case · 2–3=Possible · 4–5=Probable · ≥6=Definite DRESS · 📋 File ADR Report →
ADR Causality & Pharmacovigilance
2 tools
💊
Naranjo Scale ⭐ Gold Standard
ADR Causality Assessment
🌐
WHO-UMC
WHO Causality Categories
Clinical Criteria
WHO-UMC Category
—
Symptoms
1 tool
🌡️
VAS / NRS
Visual Analogue / Numeric Rating Scale
0
Itch Score
0
None
VAS (10 cm line) and NRS (0–10 verbal) are clinically equivalent
❑ References & Source Credits
Primary-source attributions for every instrument below. Attribution is not a licence. The scoring mathematics is generally free to reproduce, but instruments that reproduce verbatim questionnaire wording may be copyrighted — items tagged licence require permission from the rights-holder for clinical, commercial or digital use, regardless of citation. Verify all formulae and cut-offs against the original publication before clinical use. Items marked ⚠ could not be matched to a validated published instrument and should be replaced or removed.
Quality of Life
- DLQI — Finlay AY, Khan GK. Clin Exp Dermatol 1994;19:210–6. licence · © Cardiff Univ.
- cDLQI — Lewis-Jones MS, Finlay AY. Br J Dermatol 1995;132:942–9. licence · © Cardiff Univ.
- CADI — Motley RJ, Finlay AY. Clin Exp Dermatol 1992;17:1–3. licence · © Cardiff Univ.
- PsoriQoL — McKenna SP et al. (Galen Research). Qual Life Res 2003. licence · © Galen Research
- Skindex-16 — Chren MM et al. J Cutan Med Surg 2001;5:105–10. licence may apply
Psoriasis
- PASI — Fredriksson T, Pettersson U. Dermatologica 1978;157:238–44.
- BSA — Wallace "rule of nines" (Wallace AB, 1951); 1 palm ≈ 1% method.
- PGA — static Physician's Global Assessment (consensus / FDA guidance; no single source).
- PLSI — no validated published instrument located under this name/formula. Non-standard — replace with PASI or BSA.
- NAPSI — Rich P, Scher RK. J Am Acad Dermatol 2003;49:206–12.
- DAPSA — Schoels M et al. Ann Rheum Dis 2010; derived from Nell-Duxneuner et al. 2010.
Acne
- GAGS — Doshi A, Zaheer A, Stiller MJ. Int J Dermatol 1997;36:416–8.
- IGA (acne) — FDA Investigator's Global Assessment (2005 acne guidance).
- Pillsbury — Pillsbury DM, Shelley WB, Kligman AM. A Manual of Cutaneous Medicine, 1961.
- Leeds (revised) — O'Brien SC, Lewis JB, Cunliffe WJ. J Dermatolog Treat 1998;9:215–20.
- Goodman & Baron scar grade — Goodman GJ, Baron JA. Dermatol Surg 2006;32:1458–66.
Androgenetic Alopecia
- Hamilton–Norwood — Hamilton JB 1951; Norwood OT. South Med J 1975;68:1359–65.
- Ludwig / Savin — Ludwig E. Br J Dermatol 1977;97:247–54; Savin RC 1992.
Atopic Dermatitis
- SCORAD — European Task Force on Atopic Dermatitis. Dermatology 1993;186:23–31.
- EASI — Hanifin JM et al. Exp Dermatol 2001;10:11–8.
- AD-PGA / vIGA-AD — Simpson E et al. J Am Acad Dermatol 2020 (validated IGA for AD).
- ADSI — van Leent EJM et al. Arch Dermatol 1998;134:805–9.
Vitiligo
- VASI — Hamzavi I et al. Arch Dermatol 2004;140:677–83.
- Vitiligo BSA — rule-of-nines surface estimate.
- VIDA — Njoo MD, Das PK, Bos JD, Westerhof W. Arch Dermatol 1999;135:407–13.
Urticaria
- UAS7 — Młynek A et al. Allergy 2008;63:777–80.
- UCT — Weller K et al. J Allergy Clin Immunol 2014;133:1365–72. licence · © Moxie GmbH
- AAS — Weller K et al. Allergy 2012;67:1289–98. licence · © Moxie GmbH
Melasma
- MASI — Kimbrough-Green CK et al. Arch Dermatol 1994;130:727–33.
- mMASI — Pandya AG et al. J Am Acad Dermatol 2011;64:78–83.
Hair Loss · Hirsutism
- SALT — Olsen EA et al. J Am Acad Dermatol 2004;51:440–7 (NAAF).
- Ferriman–Gallwey — Ferriman D, Gallwey JD. J Clin Endocrinol Metab 1961;21:1440–7; modified (mFG) Hatch R et al. 1981.
Pemphigus / MMP · Erythroderma
- ABSIS — Pfütze M et al. Eur J Dermatol 2007;17:4–11.
- PDAI — Int. Pemphigus Definitions Committee; Murrell DF et al. J Am Acad Dermatol 2008; validated Rosenbach M et al. J Invest Dermatol 2009.
- EPICS — no validated published erythroderma instrument located under this name. Non-standard — treat as internal checklist or remove.
Hidradenitis Suppurativa
- Hurley staging — Hurley HJ. In: Dermatologic Surgery. Marcel Dekker, 1989.
- IHS4 — Zouboulis CC et al. Br J Dermatol 2017;177:1401–9.
Systemic / Connective Tissue
- MRSS — Rodnan GP 1979; modified by Clements PJ et al. J Rheumatol 1995;22:1281–5.
- SLEDAI-2K — Gladman DD, Ibañez D, Urowitz MB. J Rheumatol 2002;29:288–91.
- Vancouver Scar Scale — Sullivan T et al. J Burn Care Rehabil 1990;11:256–60.
Severe Cutaneous ADR (SCAR)
- SCORTEN — Bastuji-Garin S et al. J Invest Dermatol 2000;115:149–53.
- CRISTEN — name/purpose mismatch in this tool. Published CRISTEN is a mortality predictor (J Allergy Clin Immunol Pract 2023). For drug causality in SJS/TEN use ALDEN — Sassolas B et al. Clin Pharmacol Ther 2010;88:60–8.
- DRESS / RegiSCAR — Kardaun SH et al. Br J Dermatol 2007;156:609–11 (RegiSCAR group).
ADR Causality · Symptoms
- Naranjo — Naranjo CA et al. Clin Pharmacol Ther 1981;30:239–45.
- WHO-UMC — WHO–Uppsala Monitoring Centre causality categories.
- VAS / NRS — Visual Analogue / Numeric Rating Scale (generic patient-reported scales).
Pharmaadvance.in · Dermatology Scoring System · Designed by Dr. Harkirat (PG), Department of Pharmacology
Decision-support tool · not a substitute for clinical judgement · verify against primary sources
Decision-support tool · not a substitute for clinical judgement · verify against primary sources